Virulence and resistance factors of pathogenic Candida species;Virulenz-und resistenz-mechanismen pathogener Candida-spezies

Medizinische Welt

Volumn 48, Issue 8, 1997, Pages 352-357

  Morschhauser J ^a   Blum Oehler, G ^b   Hacker, J ^b  

^a Zentrum fur Infektionsforschung   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antimycotic drugs; Candida albicans; Fungal infections; Resistance factors; Virulence factors

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; CANDIDA ALBICANS; FUNGUS GROWTH; MEMBRANE PERMEABILITY; MYCOSIS; NONHUMAN; VIRULENCE;

EID: 0030865842     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ampel NM. Emerging disease issues and fungal pathogens associated with HIV infection. Emerging Infectious Diseases 1996; 2: 109-16.
2. Blaschke-Hellmessen R, Buchmann H, Schwarze R. Einfluß oral verabreichter Polyenantimykotika auf die Hefepilzbesiedlung des Darmtraktes: Möglichkeiten und Grenzen. Mycoses 1996; 39, Suppl 1: 33-9.
3. Bossche HV, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends in Microbiology 1994; 2: 393-400.
4. Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends in Microbiology 1995; 3: 98-104.
5. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunological strategies. Antimicrobial Agents and Chemotherapy 1996; 40: 279-91.
6. Hof H, Kretschmar M. Rationaler Einsatz von Antimykotika gegen Sproßpilzinfektionen. Immunität und Infektion 1995; 23: 209-15.
7. Hostetter MK. Interactions of Candida albicans with eukaryotic cells. ASM News 1994; 370-4.
8. Ibrahim AS, Mirbod F, Filler SG, Banno Y, Cole GT, Kitajima Y, Edwards JE Jr, Nozawa Y, Ghannoum MA. Evidence implicating phospolipase as a virulence factor of Candida albicans Infection and Immunity 1995; 63: 1993-8.
9. Lischewski A, Ruhnke M, Tennagen I, Schoman G, Morschhäuser J, Hacker J. Molecular epidemiology of Candida isolates from AIDS patients showing different Fluconazole resistance profiles. Journal of Clinical Microbiology 1995; 33: 769-71.
10. Lischewski A, Amann RI, Harmsen D, Merkert H, Hacker J, Morschhauser J. Specific detection of Candida albicans and Candida tropicalis by fluorescent in situ hybridization with an 18S rRNA-targeted oligonuclideotide probe. Microbiology 1996; 142: 2731-40.
11. Loew D, Galenik von Nystatin/Welche Medikamente stehen zur Therapie von Mykosen des Verdauungstraktes zur Verfugung? Referat bei den 3. Eckernforder Therapietagen, Eckernforde, 09.-11.06.1995.
12. Morschhauser J, Kohler G, Hacker J, Gibt es Pathogenitätsfaktoren bei Pilzen? Mycoses 1996; 39, Suppl 1: 51-4
13. Odds FC. Candida species and virulence. ASM News 1994; 60: 313-8.
14. Perfect JR. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrobial Agents and Chemotherapy 1996; 40: 1577-83.
15. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clinical Infectious Diseases 1996; 22: 89-94.
16. Ruchel R. Pathogenität von Candida albicans. Immunitat und Infektion 1991; 19: 108-11.
17. Soll DR. Gene regulation during high-frequency switching in Candida albicans. Microbiology 1997; 143: 279-88.
18. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental fac- tors. Journal of Bacteriology 1995; 177: 5215-21.
19. Yu L, Lee KK, Paranchyn W, Hodges RS, Irvin RT. Use of synthetic peptides to confirm that the Pseudomonas aeruginosa PAK pilus adhesin and the Candida albicans fimbrial adhesin possess a homologous receptor-binding domain. Molecular Microbiology 1996; 19: 1107-16.